Related Experiment Video
Updated: Jun 13, 2025
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Alan Halim1, Sujan Kumar Mondal2, Nasreen Al-Qadi1
1Precision Health Program, Michigan State University.
Abstract:
Metastatic breast cancer is a devastating disease with very limited therapeutic options, calling for new therapeutic strategies. Oncogenic miRNAs have been shown to be associated with the metastatic potential of breast cancer and are implicated in tumor cell migration, invasion, and viability. However, it can be difficult to deliver an inhibitory RNA molecule to the tissue of interest. To overcome this challenge and deliver active antisense oligonucleotides to tumors, we utilized magnetic iron oxide nanoparticles as a delivery platform. These nanoparticles target tissues with increased vascular permeability, such as sites of inflammation or cancer. Delivery of these nanoparticles can be monitored in vivo by magnetic resonance imaging (MRI) due to their magnetic properties. Translation of this therapeutic approach into the clinic will be more accessible because of its compatibility with this relevant imaging modality. They can also be labeled with other imaging reporters such as a Cy5.5 near-infrared optical dye for correlative optical imaging and fluorescence microscopy. Here, we demonstrate that nanoparticles labeled with Cy5.5 and conjugated to therapeutic oligomers targeting oncogenic miRNA-10b (termed MN-anti-miR10b, or "nanodrug") administered intravenously accumulate in metastatic sites, opening a possibility for therapeutic intervention of metastatic breast cancer.
Insights
Magnetic nanoparticles deliver anti-miRNA therapies to metastatic breast cancer sites. This nanodrug approach, trackable by MRI, offers a promising new strategy for treating advanced cancers.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Metastatic breast cancer lacks effective treatments, necessitating novel therapeutic strategies.
- Oncogenic microRNAs (miRNAs) drive cancer metastasis, but delivering inhibitory RNA is challenging.
- Targeted delivery systems are crucial for effective RNA-based cancer therapies.
Purpose of the Study:
- To develop and evaluate magnetic iron oxide nanoparticles for targeted delivery of antisense oligonucleotides against oncogenic miRNA-10b in metastatic breast cancer.
- To assess the in vivo accumulation and imaging capabilities of these targeted nanoparticles.
Main Methods:
- Conjugation of therapeutic oligomers targeting miRNA-10b to magnetic iron oxide nanoparticles (MN-anti-miR10b).
- Labeling nanoparticles with Cy5.5 for optical imaging and MRI compatibility for in vivo tracking.
- Intravenous administration of the nanodrug in a preclinical model to evaluate accumulation at metastatic sites.
Main Results:
- Nanoparticles successfully targeted and accumulated in metastatic breast cancer sites.
- The nanodrug, MN-anti-miR10b, demonstrated potential for therapeutic intervention.
- In vivo tracking was feasible using MRI and optical imaging.
Conclusions:
- Magnetic iron oxide nanoparticles serve as an effective platform for delivering therapeutic antisense oligonucleotides to metastatic breast cancer.
- This nanodrug approach, combined with MRI monitoring, shows promise for clinical translation in treating metastatic breast cancer.
- Targeted delivery of anti-miRNA agents via nanoparticles offers a new therapeutic avenue for advanced breast cancer.
